How Pharmacists Lead Managed Care Medication Adherence
- aPHP
- Feb 15
- 11 min read
Updated: Feb 16
Executive Summary
In managed care, medication adherence functions as a structural performance indicator that shapes quality ratings, reimbursement alignment, and total cost of care across Medicaid populations.
This white paper examines how pharmacists lead managed care medication adherence by embedding clinical oversight, pharmacy benefit strategy, and population health analytics within enterprise governance. Within Medicaid managed care organizations (MCOs), adherence performance directly influences HEDIS benchmarks, STAR ratings, chronic disease outcomes, and the sustainability of value-based contracts.
Medication adherence also operates as an equity indicator. Chronic conditions tied to adherence performance, including cancer, diabetes, cardiovascular disease and hypertension, disproportionately affect Black communities. When adherence strategies are operationalized at scale, pharmacists translate performance gaps into measurable quality improvements within value-based reimbursement systems.
Managed care medication adherence improves when pharmacists function as embedded infrastructure within quality, reimbursement, and population health systems.
This paper outlines the governance framework, operational execution model, financial outcomes, equity implications, and policy considerations that shape pharmacist-led adherence strategies in Medicaid managed care.
Managed care medication adherence improves when pharmacists function as embedded infrastructure within quality, reimbursement, and population health systems.
Purpose and Scope
This white paper evaluates managed care medication adherence as a structural performance function within Medicaid health plans and defines the operational role pharmacists play in strengthening medication adherence in managed care environments.
Rather than revisiting why adherence matters clinically, this paper focuses on how adherence is operationalized inside managed care systems and how pharmacists convert strategy into measurable execution.
Specifically, this analysis:
Defines the structural and financial drivers of medication adherence in managed care
Presents a pharmacist-led governance and execution framework
Demonstrates Medicaid case implementation and performance impact
Examines financial, quality, and utilization outcomes
Analyzes equity, policy, and workforce implications
The scope centers on Medicaid managed care organizations, value-based contracting environments, and population health pharmacy infrastructure, where medication adherence in managed care directly influences quality ratings, reimbursement alignment, and system accountability.
The Challenge of Medication Adherence
In managed care, medication adherence functions as a system performance indicator, shaping quality scores, reimbursement models, and the total cost of care across Medicaid populations.
Medicaid managed care organizations (MCOs) are evaluated on adherence measures tied to high-burden chronic conditions, including:
Cancer
Diabetes
Hypertension
Hyperlipidemia
These measures, assessed using the proportion of days covered (PDC), directly influence HEDIS medication adherence performance and plan-level STAR ratings.
When managed care medication adherence declines, the downstream effects are immediate and measurable:
Increased emergency department utilization
Avoidable hospital admissions
Escalating chronic disease burden
Financial risk tied to unmet value-based contract benchmarks
In this environment, medication adherence in managed care is a financial, operational, and policy priority. Improving performance requires structured population health pharmacy interventions, claims-based analytics, and coordinated outreach models to shape the health of diverse populations.
Within this performance environment, the question becomes operational: who controls adherence execution inside managed care systems?
Pharmacist Leadership in Managed Care
Within managed care systems, medication adherence performance is governed by pharmacist-led interventions.
Pharmacists operate at the intersection of clinical decision-making, pharmacy benefit design, and managed care performance analytics. This positioning makes them essential to medication adherence improvement in Medicaid managed care organizations (MCOs).
In managed care medication adherence programs, pharmacists:
Analyze claims-based medication adherence data to identify high-risk Medicaid members
Stratify populations using proportion of days covered (PDC) benchmarks and HEDIS performance thresholds
Align formulary strategy with value-based prescribing principles
Design targeted outreach campaigns for non-adherent enrollees
Coordinate with case managers, physicians, and other interdisciplinary care professionals
Track plan-level adherence performance tied to STAR ratings and value-based contract incentives
Unlike most healthcare providers, pharmacists maintain longitudinal visibility into refill behavior, therapy gaps, therapeutic duplication, step-therapy barriers, and prior-authorization delays. This comprehensive medication access oversight positions pharmacists to intervene at the root-cause level rather than responding to downstream complications.
In Medicaid managed care environments, where structural barriers shape adherence patterns, pharmacist-led strategies integrate data analytics with direct patient engagement. The result is dual impact: improved quality metrics for health plans and greater clinical stability for high-risk populations.
Managed care medication adherence performance depends on structural integration. Individual pharmacist leadership drives execution, while infrastructure sustains plan-level outcomes.
Medicaid Managed Care Adherence Programs
Medication adherence programs in Medicaid managed care require more than outreach campaigns. They require structural integration.
Embedding pharmacist-led adherence programs into managed care operations elevates medication adherence into a formal performance function. These programs consist of population health pharmacy teams that serve as operational infrastructure, aligning adherence strategies with benefit design, care management workflows, and value-based contract execution.
In these systems:
Adherence performance is tracked within enterprise quality dashboards
Outreach workflows are aligned with plan-level contract benchmarks
Telepharmacy platforms are integrated into population health operations
Care management teams include pharmacy as a performance partner
The medication access strategy is aligned with reimbursement design and risk contracts
This structure positions medication adherence as a core managed care function. When embedded at this level, pharmacist-led Medicaid adherence programs strengthen four interconnected domains:
Clinical performance: Improving chronic disease control across defined populations
Quality accountability: Elevating HEDIS and STAR adherence performance
Equity execution: Targeting high-risk Medicaid members through structured, data-informed outreach
Financial sustainability: Reducing avoidable utilization under value-based contracts
In this model, pharmacists serve as core adherence infrastructure within Medicaid managed care systems, converting strategy into measurable plan performance. Once the adherence strategy is structurally embedded, execution follows a defined operational framework. High-performing Medicaid plans rely on repeatable components rather than isolated initiatives.
Framework for Managed Care Medication Adherence
In Medicaid managed care environments, pharmacist-led adherence programs follow a defined framework that integrates analytics, outreach execution, benefit alignment, and performance governance.
A pharmacist-led managed care medication adherence framework consists of five interconnected components:
Risk Stratification and Performance Monitoring
Targeted Outreach and Telepharmacy Engagement
Value-Based Prescribing Alignment
SDOH-Informed Intervention Design
Performance Reporting and Policy Feedback
Risk Stratification and Performance Monitoring
Managed care medication adherence begins with the precise identification of members falling below performance thresholds.
Pharmacists analyze:
Proportion of Days Covered (PDC)
HEDIS adherence benchmarks
Claims-based refill gaps
High-cost utilization trends
This analytic layer isolates performance risk and prioritizes intervention based on measurable exposure to quality penalties and avoidable utilization.
Targeted Outreach and Telepharmacy Engagement
Pharmacists deploy structured telepharmacy and remote consultation models to address adherence barriers among high-risk Medicaid members.
Pharmacist-led outreach initiatives:
Resolve refill delays
Address prior authorization barriers
Reinforce disease-specific education
Identify adverse drug reactions
Close care gaps tied to quality measures
Telepharmacy operationalizes adherence engagement by extending pharmacist oversight beyond physical access constraints.
Value-Based Prescribing Alignment
Medication adherence improves when formulary design and prescribing strategies align with value-based contracting structures.
Pharmacists:
Review therapeutic duplication
Recommend cost-effective therapeutic alternatives
Lead deprescribing initiatives to reduce unnecessary medication burden
Align prescribing patterns with population health performance goals
This alignment ensures adherence strategy strengthens both clinical outcomes and plan-level financial performance.
SDOH-Informed Intervention Design
Pharmacists embed SDOH-informed strategies into adherence workflows, including:
Closed-loop referrals to community resources
Transportation and medication delivery coordination
Food support program referrals
Collaboration with community health workers
This integrated approach addresses the upstream drivers of non-adherence within high-risk populations.
Performance Reporting and Policy Feedback
Pharmacists convert adherence outcomes into structured feedback loops for health plan leadership and policymakers.
This includes:
Advising on formulary and benefit adjustments
Recommending policy refinements
Supporting performance-based value-based care contracts
Presenting adherence performance trends to drug utilization review (DUR) boards
Adherence performance strengthens when the pharmacy team operates across both clinical and governance domains.
Case Study: Pharmacist Leadership in Medicaid Managed Care
The impact of a pharmacist-led managed care medication adherence strategy is best demonstrated through structured implementation within Medicaid managed care environments.
While serving as a population health clinical pharmacist within a Managed Care Organization (MCO), Dr. La Kesha Y. Farmer led multiple Medicaid medication adherence initiatives designed to close quality performance gaps and improve chronic disease outcomes among high-risk populations.
Her adherence governance model integrated:
Claims-based identification of non-adherent, high-risk Medicaid members
Structured telepharmacy outreach workflows
Culturally responsive communication frameworks
Alignment with HEDIS medication adherence benchmarks
Direct coordination with case managers and medical directors
Policy-informed formulary access optimization
These interventions were embedded within enterprise quality governance structures and aligned with value-based reimbursement incentives. Medication adherence was positioned as a plan-level performance lever rather than an isolated outreach function.
Measurable Impact
Under this framework, pharmacist-led medication adherence initiatives contributed to:
Improved adherence performance among high-risk Medicaid populations
Closure of treatment gaps tied to chronic disease metrics
Reduction in avoidable utilization
Strengthened quality performance across managed care benchmarks
State-Level Validation and Contract Significance
Dr. Farmer presented pharmacist-led medication adherence best practices to the Global Medi-Cal Drug Utilization Review (DUR) Board at the California Department of Health Care Services (DHCS).
This engagement signaled more than academic contribution. It demonstrated that pharmacist-driven adherence governance had relevance at the state oversight level, aligning clinical execution with regulatory performance expectations.
State-level visibility reinforced the health plan’s competitive position in DHCS-aligned procurement and request-for-proposal (RFP) evaluation processes. External stakeholder recognition validated this pharmacist-led adherence strategy as a measurable asset within Medicaid contract environments.
This case illustrates a broader principle:
When pharmacists are embedded within managed care medication-adherence infrastructure, their work influences clinical outcomes, quality governance, reimbursement alignment, and contract competitiveness.
Financial and System-Level Outcomes
Medication adherence performance directly influences plan revenue, risk adjustment, and quality incentive payments. Pharmacist-led medication adherence programs strengthen financial and operational performance by improving:
HEDIS medication adherence rates
STAR-related quality benchmarks
Emergency department utilization trends
Hospital readmission rates
Total cost of care under value-based contracts
Evidence from Medicaid adherence initiatives demonstrates measurable system impact, including:
A 15% increase in adherence rates among high-risk participants¹
A 25% reduction in hospital readmissions through chronic disease optimization¹
Cost savings aligned with managed care quality and reimbursement targets¹
These outcomes confirm that medication adherence is a financial performance strategy within managed care systems. When pharmacists operate as embedded adherence infrastructure, quality performance, utilization control, and reimbursement alignment move in the same direction.
Black Health and Managed Care Adherence
In Medicaid managed care, medication adherence is both a quality metric and an equity indicator. Black communities carry elevated burdens of cancer, hypertension, diabetes complications, and preventable cardiovascular mortality, conditions directly tied to adherence performance benchmarks used in HEDIS and STAR-ratings frameworks.
Adherence gaps reflect structural constraints, including medication access instability, fragmented care coordination, inconsistent formulary alignment, and trust barriers within healthcare systems.
Pharmacist-led managed care medication adherence strategy converts these disparities into measurable plan-level improvement. Through structured risk stratification, culturally responsive telepharmacy outreach, formulary optimization, and SDOH-integrated workflows, pharmacists operationalize adherence as a governance function within Medicaid managed care systems.
When embedded at the enterprise level, this model produces dual alignment:
Stronger value-based quality performance
Improved chronic disease stability within Black communities
This approach reflects aPHP’s mission to develop pharmacy skills to address Black health challenges through the design of structured, measurable systems.
Policy and Provider Recognition
The evolution of managed care medication adherence strategies reflects a broader shift in pharmacists' recognition within healthcare systems.
Following the 1951 Durham-Humphrey Amendment, pharmacists were structurally repositioned into dispensing-focused roles. In contemporary Medicaid managed care environments, this dynamic is shifting as pharmacist-led population health strategies demonstrate measurable improvements in quality and financial performance.
Pharmacists leading managed care medication adherence initiatives:
Inform formulary and benefit policy decisions
Influence value-based reimbursement design
Advise Medicaid program leadership on adherence performance trends
Align medication adherence strategy with public health and equity priorities
This progression strengthens the case for pharmacist provider recognition by demonstrating quantifiable system value within managed care frameworks. Managed care medication adherence thus serves as a practical policy bridge, connecting clinical oversight, financial accountability, and population health performance.
Barriers to Pharmacist Integration
Despite a measurable impact, structural constraints continue to limit the full integration of pharmacists into managed care adherence strategies.
Key barriers include:
Inconsistent reimbursement models for pharmacist-led adherence services
Fragmented interoperability between pharmacy claims, medical data, and care management platforms
Underdeployment of pharmacist analytics expertise within quality governance structures
Insufficient workforce training in managed care performance metrics and value-based reimbursement
These constraints are structural rather than clinical.
Advancing pharmacist leadership in Medicaid managed care requires formal integration of pharmacy into adherence infrastructure, reimbursement design, and performance governance frameworks.
The Future of Managed Care Medication Adherence
Managed care medication adherence is central to Medicaid performance architecture. It shapes quality ratings, reimbursement alignment, utilization management, and long-term cost control.
Pharmacists stand at the operational core of this architecture. Positioned at the intersection of clinical oversight, pharmacy benefit design, and population health analytics, they convert medication adherence in managed care from a reporting metric into a governed performance function.
Sustained advancement requires deliberate system design:
Formal integration of pharmacists into plan-level quality governance
Workforce development aligned with managed care analytics and value-based performance
Reimbursement models that recognize pharmacist-led adherence strategy as infrastructure
Policy frameworks that embed pharmacy into Medicaid population health execution
Continued expansion of telepharmacy and data-informed engagement models
In healthcare systems where Black communities experience disproportionate chronic disease burden and medication access barriers, managed care medication adherence strategy becomes a lever for addressing structural inequities through measurable plan performance.
When pharmacists function as embedded performance leaders, managed care medication adherence strengthens across quality, equity, and financial domains simultaneously.
The evolution is structural.
The expectation is measurable.
The opportunity is operational.
Managed care medication adherence is optimized when pharmacists are fully integrated into the governance, analytics, and strategic execution of Medicaid health plans.
Academy of Population Health Pharmacy | Policy & Performance Series | aPHP-PPS-2026-01
The Academy of Population Health Pharmacy
Policy & Performance Series
Building pharmacy infrastructure designed to address structural drivers of inequity within managed care systems, particularly those shaping Black health outcomes.
References
Centers for Disease Control and Prevention (CDC). "Medication Therapy Management in Medicaid." CDC. Updated March 2021. Accessed December 26, 2024. https://www.cdc.gov/cardiovascular-resources/media/MTM_in_Medicaid-508.pdf. Accessed February 13, 2025.
Centers for Disease Control and Prevention (CDC). "Social Determinants of Health (SDOH)." CDC.gov, 17 Jan. 2024, www.cdc.gov/about/priorities/why-is-addressing-sdoh-important.html. Accessed February 13, 2025.
Centers for Medicare & Medicaid Services (CMS). "Accountable Care and Accountable Care Organizations." Www.cms.gov, 2024, www.cms.gov/priorities/innovation/key-concepts/accountable-care-and-accountable-care-organizations. Accessed February 13, 2025.
Centers for Medicare & Medicaid Services (CMS). "Consumer Assessment of Healthcare Providers & Systems (CAHPS)." Www.cms.gov, 1 Apr. 2024, www.cms.gov/data-research/research/consumer-assessment-healthcare-providers-systems. Accessed February 13, 2025.
Centers for Medicare & Medicaid Services (CMS). "CMS’ Value-Based Programs." Www.cms.gov, 2023, www.cms.gov/medicare/quality/value-based-programs. Accessed February 13, 2025.
Chan, Mabel, et al. "Pharmacist-Led Deprescribing for Patients With Polypharmacy and Chronic Disease States: A Retrospective Cohort Study." J Pharm Pract. 2023 Oct; 36(5):1192-1200. Accessed February 13, 2025. https://pubmed.ncbi.nlm.nih.gov/35522029/.
Daly, Christopher J., and David M. Jacobs. "Implementing a Social Determinants of Health Program." University at Buffalo School of Pharmacy and Pharmaceutical Sciences, n.d., Community Pharmacy Foundation. Accessed 31 Jan. 2025.
Dassau, E., et al. "Closing the Loop." International Journal of Clinical Practice, vol. 65, Feb. 2011, pp. 20–25, https://doi.org/10.1111/j.1742-1241.2010.02575.x. Accessed February 13, 2025.
Greer N, Bolduc J, Geurkink E, et al. "Pharmacist-Led Chronic Disease Management: A Systematic Review of Effectiveness and Harms Compared to Usual Care [Internet]." Washington (DC): Department of Veterans Affairs (US); 2015 Oct. INTRODUCTION. Available from: https://www.ncbi.nlm.nih.gov/books/NBK362935/
HealthLeaders. "New Study Identifies Health Plan SDoH Data Challenges." Healthleadersmedia.com, 2024, www.healthleadersmedia.com/payer/new-study-identifies-health-plan-sdoh-data-challenges. Accessed 19 July 2025.
Institute for Healthcare Improvement (IHI). "The Triple Aim: Care, Health, and Cost." Ihi.org, 2025, www.ihi.org/library/publications/triple-aim-care-health-and-cost. February 13, 2025.
Medicaid. "Drug Utilization Review (DUR)." Medicaid.gov, 2022, www.medicaid.gov/medicaid/prescription-drugs/drug-utilization-review. Accessed February 13, 2025.
Moczygemba, Leticia R, et al. "Comprehensive Health Management Pharmacist-Delivered Model: Impact on Healthcare Utilization and Costs." Am J Manag Care, vol. 25, no. 11, 14 Nov. 2019, https://www.ajmc.com/view/comprehensive-health-management-pharmacistdelivered-model-impact-on-healthcare-utilization-and-costs?Accessed 31 Jan. 2025.
Montgomery, E., Sherod-Harris, T., Adkins, M., & Hinely, M. "Impact of Pharmacy Involvement on Care Gap Closure in Managed Medicaid Patients." Am J of Health-System Pharmacy, Published 21 Nov. 2024, doi:10.1093/ajhp/zxae328. Accessed January 30, 2024. https://pubmed.ncbi.nlm.nih.gov/39570898/. Accessed 31 Jan. 2025.
North Carolina Department of Natural and Cultural Resources (NC DNCR). "Carl Durham, Champion of Pharmaceutical Reform." Www.dncr.nc.gov, 26 Oct. 2016, www.dncr.nc.gov/blog/2016/10/26/carl-durham-champion-pharmaceutical-reform. 18 July 2025
Peterson Foundation. "How Does the U.S. Healthcare System Compare to Other Countries?" Peterson Foundation, 20 Dec. 2024, https://www.pgpf.org/article/how-does-the-us-healthcare-system-compare-to-other-countries/. Accessed February 13, 2025.
Pharmacy Quality Alliance (PQA). “Adherence Measures.” Www.pqaalliance.org, www.pqaalliance.org/adherence-measures. Accessed February 13, 2025.
Presley, Kempton. "Contributor: A Fresh Approach to Medication Adherence—Best Practices for Improving Outcomes and Star Ratings." AJMC, 25 Mar. 2025, www.ajmc.com/view/contributor-a-fresh-approach-to-medication-adherence-best-practices-for-improving-outcomes-and-star-ratings. Accessed February 13, 2025.
Scotti, Samantha. “Value-Based Care in the Commercial Sector and with Multi-Payer Arrangements.” Www.ncsl.org, 9 Jan. 2024, www.ncsl.org/health/value-based-care-in-the-commercial-sector-and-with-multi-payer-arrangements. Accessed 25 June 2025.
Shen, Megan Johnson, et al. "The Effects of Race and Racial Concordance on Patient-Physician Communication: A Systematic Review of the Literature." Journal of Racial and Ethnic Health Disparities, vol. 5, no. 1, 8 Mar. 2018, pp. 117–140, https://doi.org/10.1007/s40615-017-0350-4. Accessed February 13, 2025.
Smith, Alex. "Deprescribing Super Special III: Constance Fung, Emily McDonald, Amy Linsky, and Michelle Odden." A Geriatrics and Palliative Care Podcast for Every Healthcare Professional, 23 Jan. 2025, geripal.org/deprescribing-super-special-iii-constance-fung-emily-mcdonald-amy-linsky-and-michelle-odden/. Accessed 19 July 2025. Accessed February 13, 2025.
Texas Tech University. "The History of Pharmacy." Ttuhsc.edu, 2020, www.ttuhsc.edu/pharmacy/museum/pharmacy.history.aspx. Accessed 31 Jan. 2025.
The American Journal of Managed Care. "Cost Savings From an mHealth Tool for Improving Medication Adherence." Am J Manag Care. Published September 1, 2023. Accessed December 26, 2024. https://www.ajmc.com/view/cost-savings-from-an-mhealth-tool-for-improving-medication-adherence. Accessed February 13, 2025.
The American Journal of Managed Care. "Reducing Barriers to Medication Access and Adherence for ACA and Medicaid Participants: A Peer-to-Peer Community-Based Approach." Am J Manag Care. Published April 22, 2022. Accessed December 26, 2024. https://www.ajmc.com/view/reducing-barriers-to-medication-access-and-adherence-for-aca-and-medicaid-participants-a-peer-to-peer-community-based-approach. Accessed February 13, 2025.
Weiser P. "How Pharmacists Can Influence HEDIS Measures and Value-Based Care." Outcomes™ Blog. September 21, 2022. Accessed December 29, 2024. https://blog.getoutcomes.com/perspectives/how-pharmacists-can-influence-hedis-measures-and-value-based-care. Accessed February 13, 2025.
World Health Organization. "Frequently Asked Questions." Www.who.int, 2024, www.who.int/about/frequently-asked-questions. Accessed February 13, 2025.